JNJ Latest Headlines

Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program

at seekingalpha.com (Fri, 22-Nov 11:50 AM)

Johnson & Johnson seeks FDA approval for its ulcerative colitis treatment

at seekingalpha.com (Fri, 22-Nov 8:48 AM)

Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and others

at seekingalpha.com (Fri, 22-Nov 8:40 AM)

Zevra Niemann-Pick disease type C drug Miplyffa now available

at seekingalpha.com (Thu, 21-Nov 5:29 PM)

Optimism over global healthcare sector rises: Jefferies

at seekingalpha.com (Thu, 21-Nov 1:45 PM)

Johnson & Johnson’s Promising Pharmaceutical Developments Justify Buy Rating

at www.tipranks.com (Thu, 21-Nov 1:17 AM)

Johnson & Johnson’s M&A Strategy in Cardiovascular Devices Supports Hold Rating

at www.tipranks.com (Wed, 20-Nov 4:56 AM)

Large caps in trouble? Key takeaways from Tommy Tuberville's latest trades

at seekingalpha.com (Tue, 19-Nov 12:09 PM)

Balanced Hold Rating for JNJ’s Icotrokinra Amid Efficacy Concerns and Healthcare Policy Uncertainties

at www.tipranks.com (Tue, 19-Nov 5:56 AM)

J&J unveils positive phase 3 results for icotrokinra for plaque psoriasis

at seekingalpha.com (Mon, 18-Nov 4:59 PM)

Halozyme plans finance $2.1 takeover of Evotech in cash: report

at seekingalpha.com (Sun, 17-Nov 6:28 PM)

Halozyme plans to finance $2.1 takeover of Evotech in cash: report

at seekingalpha.com (Sun, 17-Nov 6:28 PM)